We target therapeutics to human heart function, taking a precision approach to drug development and capturing the adult heart clinical phenotype. This is powered by our scalable, authentic and predictive discovery engine - HeartDyno. HeartDyno is built with engineered human cardiac organoids, scalably deployed to drive a multi-omics data-driven approach. It rapidly uncovers novel therapeutic targets and candidates that offer superior efficacy and safety profiles in humans. Dynomics’ approach is validated through collaboration with top pharmaceutical companies, top-tier scientific publications, and we are progressing assets targeting heart failure, affecting 4% of the US population and where current treatments provide a 50% 5-year survival rate.
Something looks off?